Discontinue therapy if becomes pregnant while taking Rostatin. Perform liver functions tests before & at 12-wk after initiation of therapy or any increase in dosage & periodically thereafter. Reduce dose or discontinue if increases in AST or ALT conc of 3x ULN or higher persist. Increased risk of myopathy in patients ≥65 yr, particularly women, hypothyroidism, receiving dose exceeding recommended dose range of 5-40 mg daily, Asian patients, & renal impairment. Concomitant use w/ cyclosporine, niacin, fibric-acid derivatives, macrolide antibiotics, certain azole antifungals & alcohol; ketoconazole, spironolactone, cimetidine. Discontinue use if serum CK conc elevation or myopathy occurs. Temporarily withhold therapy in acute; serious condition suggestive of myopathy or acute renal failure predisposing development secondary to rhabdomyolysis (eg, sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine or electrolyte disorders, uncontrolled seizures. Attempt vigorously control of serum cholesterol prior to therapy.